Evidence map›Paper›PMID 36620226›Full record

ReviewFrontiers in physiology2022

TREK-1 in the heart: Potential physiological and pathophysiological roles.

Emilie Bechard, Jamie Bride, Jean-Yves Le Guennec, Fabien Brette, Marie Demion

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Mechanotransduction-Driven Modulation ofInternational journal of molecular sciences · 2025
    Article
  8. The two-pore KAmerican journal of physiology. Heart and circulatory physiology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Emilie BechardPhyMedExp, Université de Montpellier, Inserm U1046, UMR CNRS 9412, Montpellier, France.
Jamie BridePhyMedExp, Université de Montpellier, Inserm U1046, UMR CNRS 9412, Montpellier, France.
Jean-Yves Le GuennecPhyMedExp, Université de Montpellier, Inserm U1046, UMR CNRS 9412, Montpellier, France.
Fabien BrettePhyMedExp, Université de Montpellier, Inserm U1046, UMR CNRS 9412, Montpellier, France.
Marie DemionPhyMedExp, Université de Montpellier, Inserm U1046, UMR CNRS 9412, Montpellier, France.
Centre National de la Recherche Scientifique · FRInserm · FRPhysiologie et Médecine Expérimentale du Coeur et des Muscles · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TREK-1 channel belongs to the TREK subfamily of two-pore domains channels that are activated by stretch and polyunsaturated fatty acids and inactivated by Protein Kinase A phosphorylation. The activation of this potassium channel must induce a hyperpolarization of the resting membrane potential and a shortening of the action potential duration in neurons and cardiac cells, two phenomena being beneficial for these tissues in pathological situations like ischemia-reperfusion. Surprisingly, the physiological role of TREK-1 in cardiac function has never been thoroughly investigated, very likely because of the lack of a specific inhibitor. However, possible roles have been unraveled in pathological situations such as atrial fibrillation worsened by heart failure, right ventricular outflow tract tachycardia or pulmonary arterial hypertension. The inhomogeneous distribution of TREK-1 channel within the heart reinforces the idea that this stretch-activated potassium channel might play a role in cardiac areas where the mechanical constraints are important and need a particular protection afforded by TREK-1. Consequently, the main purpose of this mini review is to discuss the possible role played by TREK -1 in physiological and pathophysiological conditions and its potential role in mechano-electrical feedback. Improved understanding of the role of TREK-1 in the heart may help the development of promising treatments for challenging cardiac diseases.

Indexed as

atrial fibrillationK2P2.1myocardial infarctionRVOTTREK-1

Identifiers

PMID36620226
PMCPMC9815770
OpenAlexW4312186569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.